Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.34 |
| ▸ | PIM1 | P11309 | 3/20 | 0.34 |
| ▸ | AURKA | O14965 | 2/20 | 0.34 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.34 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.34 |
| ▸ | RET | P07949 | 2/20 | 0.34 |
| ▸ | IGF1R | P08069 | 2/20 | 0.34 |
| ▸ | CLK2 | P49760 | 2/20 | 0.34 |
| ▸ | GSK3A | P49840 | 2/20 | 0.34 |
| ▸ | GSK3B | P49841 | 2/20 | 0.34 |
| ▸ | PRKX | P51817 | 2/20 | 0.34 |
| ▸ | BTK | Q06187 | 2/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.34 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.34 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29574753 | 1.00 | CSNK2A1 (0.34) | CSNK2A1PIM1AURKADAPK3PRKD3 | |
| SCHEMBL16774129 | 0.80 | CSNK2A1 (0.40) | CSNK2A1PIM1AURKADAPK3PRKD3 | |
| SCHEMBL26106496 | 0.80 | PARP1 (0.40) | CSNK2A1PIM1PARP1PIM2AXL | |
| SCHEMBL31347215 | 0.80 | MEN1 (0.36) | CSNK2A1PIM1IGF1RCLK2GSK3A | |
| SCHEMBL30611884 | 0.80 | PARP1 (0.40) | CSNK2A1PIM1PARP1PIM2AXL | |
| SCHEMBL10399191 | 0.80 | DPP4 (0.34) | CSNK2A1PIM1AURKADAPK3PRKD3 | |
| SCHEMBL22757469 | 0.80 | PIM1 (0.36) | CSNK2A1PIM1AURKADAPK3PRKD3 | |
| SCHEMBL10626643 | 0.71 | CDK2 (0.39) | AURKAGSK3BABL1METCDK7 | |
| SCHEMBL18114683 | 0.69 | MAPT (0.42) | LRRK2MAPTKDM4EGAA | |
| SCHEMBL127024 | 0.68 | AXL (0.48) | CSNK2A1PIM1AURKADAPK3PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125378-A2 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2026-05-07 | — | — | US | disclosed |
| US-20250353846-A1 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2025-11-20 | — | — | US | disclosed |
| EP-4634186-A1 | 2,6,9-TRISUBSTITUTED PURINES | Astrazeneca AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| US-12441744-B2 | 2,6,9-trisubstituted purines | ASTRAZENECA AB | 2025-10-14 | — | — | US | disclosed |
| US-12435095-B2 | Substituted morpholines as ATR kinase inhibitors | SHANGHAI ANNOVA BIOTECHNOLOGY CO., LTD. (CN) | 2025-10-07 | — | — | US | disclosed |
| US-12421273-B2 | Ectonucleotidase inhibitors and methods of use thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2025-09-23 | — | — | US | disclosed |
| US-20250197425-A1 | 2,6,9-TRISUBSTITUTED PURINES | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| US-20250179070-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS | REPARE THERAPEUTICS INC (CA) | 2025-06-05 | — | — | US | disclosed |
| WO-2025080788-A1 | CCR4 INHIBITORS AND METHODS OF USE THEREOF | RAYTHERA, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-12264155-B2 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors | REPARE THERAPEUTICS INC. (CA) | 2025-04-01 | — | — | US | disclosed |
| US-20140114070-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-04-24 | — | — | US | disclosed |
| WO-2013095761-A1 | IMIDAZOPYRIDINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013095761-A1 | IMIDAZOPYRIDINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-06-27 | — | — | WO | disclosed |
| EP-2350078-A2 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2011-08-03 | — | — | EP | disclosed |
| US-20100183564-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2010-07-22 | — | — | US | disclosed |
| WO-2010059401-A2 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2010-05-27 | — | — | WO | disclosed |
| US-7358235-B2 | Analogs of nitrobenzylthioinosine | GRUENENTHAL GMBH (DE) | 2008-04-15 | — | — | US | disclosed |
| US-7358235-B2 | Analogs of nitrobenzylthioinosine | GRUENENTHAL GMBH (DE) | 2008-04-15 | — | — | US | disclosed |
| US-4780452-A | ANTIINFLAMMATORY AGENTS, ANTIPYRETICS | BURROUGHS WELLCOME CO. (US) | 1988-10-25 | — | — | US | disclosed |
| EP-0260852-A2 | Nucleoside Analogues | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435095-B2 | Substituted morpholines as ATR kinase inhibitors | ATR, WEE1, WEE2 | CSNK2A1 322/4885PIM1 585/4885AURKA 64/4885 |
| US-20260125378-A2 | Heterocyclic Compounds | NFATC1, CD4, MALT1 | CSNK2A1 954/4885PIM1 4476/4885AURKA 2743/4885 |
| US-12421273-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | CSNK2A1 3460/4885PIM1 4578/4885AURKA 3513/4885 |
| US-20250179070-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS | ATR, CHEK2, CHEK1 | CSNK2A1 131/4885PIM1 2762/4885AURKA 177/4885 |
| US-20250353846-A1 | Heterocyclic Compounds | NFATC1, CD4, ACIN1 | CSNK2A1 580/4885PIM1 1203/4885AURKA 937/4885 |
| US-12441744-B2 | 2,6,9-trisubstituted purines | CDK2, CDK1, CCNT2 | CSNK2A1 113/4885PIM1 860/4885AURKA 147/4885 |
| US-20250197425-A1 | 2,6,9-TRISUBSTITUTED PURINES | CDK2, CDK1, CCNT2 | CSNK2A1 113/4885PIM1 860/4885AURKA 147/4885 |
| US-20140114070-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | CD47, HCLS1, CD74 | CSNK2A1 4693/4885PIM1 1708/4885AURKA 2901/4885 |
| US-20100183564-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | CD47, HCLS1, CD74 | CSNK2A1 4693/4885PIM1 1708/4885AURKA 2901/4885 |
| US-12264155-B2 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors | ATR, CHEK2, CHEK1 | CSNK2A1 131/4885PIM1 2762/4885AURKA 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.